Please login to the form below

Not currently logged in
Email:
Password:

GSK's Atriance approved in EU

The EU Commission has approved GlaxoSmithKline's leukaemia drug Atriance for the treatment of  T-cell acute lymphoblastic leukaemia and lymphoma patients unresponsive to previous chemotherapy

The EU Commission has approved GlaxoSmithKline's (GSK's) leukaemia drug Atriance (nelarabine) for the treatment of  T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) patients whose disease has not responded to, or has relapsed following treatment with at least two chemotherapy regimens.

"This is a significant and important new licence for those patients affected and their specialist physicians across Europe. Atriance may offer a valuable chance for patients with few existing treatment options to go on to have potentially curative treatment, such as a stem cell transplant", said Professor Dieter Hoelzer, from J.W.Goethe Universit‰t, Germany.

Trial results
The efficacy and safety profile of Atriance were evaluated in two, multi-centre pivotal Phase II clinical trials - one conducted in adults and one in children with refractory or relapsed T-ALL or T-LBL.

Both trials were carried out in the US in collaboration with the National cancer Institute (NCI) and published in Blood and The Journal of Clinical Oncology respectively.

The studies found that around 20 per cent of patients who received Atriance according to the licensed dosage and who had relapsed following, or were refractory to, two or more prior chemotherapy regimens, experienced a complete response, with or without restoration of normal blood cells levels.

The European Medicines Agency (EMEA) gave Atriance a positive opinion in June 2007.

 

30th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics